Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
NextCure, a clinical-stage biopharmaceutical company focused on developing first-in-class immunomedicines for cancer and immune-related diseases, will present at the BTIG Virtual Biotechnology Conference on August 11 at 9:30 am ET. A live audio webcast will be accessible on NextCure's website, with a replay available two hours post-event and archived for 30 days. The company aims to address treatment gaps for patients unresponsive to current therapies through its proprietary FIND-IO™ platform.
NextCure (Nasdaq: NXTC) provided an interim update for its NC318 phase 2 trial, announcing that it will not advance the non-small cell lung cancer and ovarian cancer cohorts into stage 2 due to disappointing biomarker data. Ongoing evaluations will determine future studies in these areas. However, the head and neck cancer cohort has shown one confirmed partial response, allowing advancement to stage 2. The company expects to release further clinical data in Q4 2020. Additionally, Chief Medical Officer Kevin Heller has resigned, effective August 4, 2020, but will continue as a consultant.
NextCure, Inc. (Nasdaq: NXTC) announced the initiation of a Phase 1/2 clinical trial for NC410, targeting immune suppression mediated by LAIR-1. This open-label trial aims to evaluate the safety, tolerability, and dosage of NC410 in patients with advanced solid tumors. The trial's Phase 1 results are expected by the second half of 2021. This marks a significant advancement in NextCure's pipeline, as it is the first company to explore LAIR proteins clinically. The firm aims to provide new treatment options for patients unresponsive to existing therapies.
NextCure, Inc. (NXTC) reported Q1 2020 results, highlighting a significant revenue increase to $22.4 million, up from $1.4 million in Q1 2019, primarily due to recognition of deferred revenue from a terminated agreement with Eli Lilly. Cash, cash equivalents, and marketable securities totaled $322.1 million. However, the company faced challenges as the COVID-19 pandemic delayed the initiation of the NC410 clinical trial and other milestones. R&D expenses rose to $10.6 million, reflecting expanded clinical activities. Notably, net income reached $9.7 million, compared to a $6.2 million loss in the prior year.
NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, will present at the BofA Securities Virtual Health Care Conference on May 13th at 9:00 am Eastern time. The event will be accessible via a live audio webcast on the company's website, with a replay available two hours post-event for 30 days. NextCure focuses on developing innovative immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform.